Merkel cell carcinoma (MCC) is a highly malignant neuroendocrine tumor of the skin whose molecular pathogenesis is not completely understood, despite the role that Merkel cell polyomavirus can play in 55e90% of cases. To study potential mechanisms driving this disease in clinically characterized cases, we searched for somatic mutations using whole-exome sequencing, and extrapolated our findings to study functional biomarkers reporting on the activity of the mutated pathways. Confirming previous results, Merkel cell polyomavirus-negative tumors had higher mutational loads with UV signatures and more frequent mutations in TP53 and RB compared with their Merkel cell polyomavirus-positive counterparts. Despite important genetic differences, the two Merkel cell carcinoma etiologies both exhibited nuclear accumulation of oncogenic transcription factors such as NFAT or nuclear factor of activated T cells (NFAT), P-CREB, and P-STAT3, indicating commonly deregulated pathogenic mechanisms with the potential to serve as targets for therapy. A multivariable analysis identified phosphorylated CRE-binding protein as an independent survival factor with respect to clinical variables and Merkel cell polyomavirus status in our cohort of Merkel cell carcinoma patients.
INTRODUCTION
Merkel cell carcinoma (MCC) is a highly malignant neuroendocrine tumor of the skin, with an increasing number of diagnosed cases and deaths attributable to the tumor. MCC has a relatively low incidence, but the mortality rate of diagnosed cases is 33%, which exceeds that of melanoma in the skin (reviewed in Hughes et al., 2014) . MCC primarily affects older and immunosuppressed patients who, at the time of diagnosis, frequently have advanced clinical stage disease. This dramatically affects the 5-year survival rate, which is 64% in patients with localized tumors, 39% in those with loco-regional metastasis, and 18% in those with distant metastasis (Sarnaik et al., 2010) .
The origin of MCC remains uncertain. The role of Merkel and/or pluripotent epidermal cells is currently under discussion (McCardle et al., 2010; Ratner et al., 1993) . Recent evidence suggests that clonal integration of Merkel cell polyomavirus (MCPyV) is one of the main etiological mechanisms by which MCC develops. It has been found in 55e90% of the cases analyzed (Becker et al., 2009; Bhatia et al., 2010; Duncavage et al., 2009; Feng et al., 2008; Garneski et al., 2009) . MCPyV expresses large, small, and 57-kDa T antigens that have the potential to inhibit retinoblastoma (RB) activity (by large T antigen) and promote MCC tumorigenesis, although the mechanisms responsible are poorly understood (Stakaityte et al., 2014) . Along with MCPyV, there is increasing evidence that sun exposure may also be a major independent etiological factor. MCC most commonly develops in areas of the skin exposed to the sun, such as the head and neck, as in other malignant skin tumors such as melanoma (Davies et al., 2002; Lunder and Stern, 1998; Rockville Merkel Cell Carcinoma Group, 2009) . In this regard, recent work by independent laboratories has shown important genetic differences between MCPyV þ and MCPyV e MCC tumors, the latter harboring higher mutational burdens with UV signatures (Goh et al., 2015; Harms et al., 2015; Wong et al., 2015) .
From a molecular perspective, the main mechanisms of transformation promoting MCCs are still partially unknown. Mutations in TP53 have been observed in 14e33% of MCC patients. They are considered a rare event in MCCs that are mostly confined to MCPyV e cases (Harms et al., 2015; Lassacher et al., 2008) . Moreover, mutations affecting PIK3CA and deregulated PI3K-mTOR activity have been observed in patient samples and cell lines (Hafner et al., 2012; Nardi et al., 2012) , and alterations in NOTCH and RAS/mitogen-activated protein kinase signaling pathways (Harms et al., 2015) have been detected in MCCs. However, these advances are not yet used to diagnose or treat the disease. Current treatment options mainly rely on surgical excision combined with loco-regional adjuvant radiation (Harring et al., 2011) .
In this study, we examined a cohort of clinically characterized MCC patients using a combination of whole-exome sequencing approaches and a selection of biomarkers, chosen on the basis of the mechanistic interpretation of the genomic data. We characterized two main MCC etiologies in our cohort: MCPyV þ tumors, which had few mutations and a high survival rate, and MCPyV e tumors, which had more genomic alterations and a worse clinical outcome. We detected a number of signaling mechanisms with the potential to participate in the development of MCC and studied these using specific endpoint immunohistochemical biomarkers to examine their activity. We found that MCPyV þ and MCPyV e tumors can share specific disease mechanisms, as implied by the detection of positive nuclear factor of activated T cells (NFAT), phosphorylated CRE-binding protein (P-CREB), and phosphorylated signal transducer and activator of transcription-3 (P-STAT) immunostaining in MCC samples. In addition, MCPyV e tumors almost exclusively developed alternative mechanisms of disease, as indicated by C-MYC and LEF1 expression in our sample series with respect to their MCPyV þ counterparts. Finally, we found a clinical correlation between P-CREB nuclear expression and a worse prognosis in MCC patients that was independent of sex, age, clinical stage, and MCPyV status.
RESULTS

Inverse correlation between MCPyV and UV mutational signature in MCC
We initially characterized the genomic variants in a series of 15 patients with MCC (henceforth referred to as the discovery cohort; see the clinical data in Table 1, and see  Supplementary Table S1 online). The mean age of patients was 75.5 years, and 53% of the study population were men. All samples corresponded to primary tumors located in sunexposed areas in eight of the patients. We generated two paired-end 101-base pair whole-exome sequencing libraries and sequenced paired tumoral and nontumoral genomic DNA for each patient. This allowed us to uniquely map an average of approximately 86 million reads per sample, which were analyzed for the presence of somatic mutations as previously described Vaque et al., 2015) . Under these conditions, the mean coverage of the target sequence was Â105 (Â53e170), with an average of 92% (range ¼ 71.25e97.07%) of the targeted bases having at least Â15 coverage (see Supplementary Table S2 online for a detailed description of the genomic analysis). Finally, our somatic mutation analyses detected 16,198 somatic singlebase mutations (SSMs) in tumor samples (range ¼ 29e3,644 in the discovery cohort of samples), of which 4,913 (range ¼ 5e1,275) are responsible for amino-acid changes (Table 1, and see Supplementary Tables S3 and S4  online) .
MCPyV status was determined by immunohistochemistry (IHC) for MCPyV T-antigen protein expression in all patients (except patients 8 and 13), followed by a confirmatory PCR analysis in a subset of cases that showed no discrepancies (see Supplementary Materials online). From a genomic perspective, we detected two clearly different subsets of patients. On one hand, those MCC lesions that tested positive for the Merkel polyomavirus (MCPyV þ ) had a low number of somatic mutations, with an average mutational index of 0.75 amino acid-changing SSMs/megabase. On the other hand, lesions that had negative test results for this virus (MCPyV e ) showed higher mutational indexes, averaging 19.81 amino acid-changing SSMs/megabase, which is comparable to values observed in cutaneous melanomas (Berger et al., 2012) . We found that all MCPyV e lesions, except that from patient 13, harbored a UV signature defined by the detection of more than 60% C>T transitions at dipyrimidine sites or more than 5% CC>TT mutations of the total number of SSMs in each case (Table 1 and Figure 1a ) (Brash, 2015; The Cancer Genome Atlas Network, 2015) . In contrast, this UV signature was not detected in MCPyV þ patients. Thus, we can conclude that the presence of MCPyV in our discovery cohort was inversely correlated with mutational indexes and the presence of UV signatures. Note. Clinical data of 15 MCC cases, including sex, age at diagnosis, location of the lesion, and stage. The genomic data from each patient are also represented. Abbreviations: AA, amino acid; C, cytosine; F, female; FF, freshly frozen; FFPE, formaldehyde-fixed paraffin-embedded; M, male; MCPyV, Merkel cell polyomavirus; MI, mutational index; SSM, somatic singlebase mutation; T, thymine. TP53  RB1  CIT  COL24A1  COL4A4  FAT4  FLNC  ITGB4  CLASP2  CDK5RAP1  HDAC2  ZBTB17  HIVEP2  EP300  MLL3  AK5  GLB1L2  PAFAH2  HK2  LCT  SMPD3  GRIN2C  PLCH1  NFATC4  PLCB1  RYR1  RYR2  CACNA1C  APC  CTNNA2  WNT6  ADCY1  ADCY4  CRTC3  GRM2  GRM6  KIDINS220  MAPK8IP3  RASGRF1  RASGRF2  RASGRP3  ERBB4  FLT4  ROS1  KDR  PIK3C2B  RPS6KB1  RPTOR  JAK3 unbiased OncodriveFM analysis (described in the Supplementary Materials and in Gonzalez-Perez and LopezBigas, 2012) using all the SSMs detected in this work (see Supplementary Table S3 ). This enabled us to detect potential driver genes like TP53, CDK5RAP1, FAT4, ADAM8, GLB1L2, OGG1, HIVEP2, and RB1 with a significant P-value (see Supplementary Table S7 online) . Moreover, using this approach we were also able to detect a number of significant gene modules from the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway that included TP53, small cell lung carcinoma, non-small cell lung cancer, melanoma, and basal cell carcinoma, to name but a few (see Supplementary  Table S8 online). We searched for the main biological and biochemical mechanisms/signaling pathways associated with each significant gene found in our analysis alongside those included in the specific KEGG gene modules detected with OncodriveFM (see Supplementary Tables S7 and S8 ). To simplify the presentation of our findings, we grouped these into functional categories. These included specific subsets of KEGG gene sets (see Supplementary Table S8 ) with redundant biological activities (points ievi as follow) or with shared mechanisms (points viieix as follow): (i) focal adhesion and extracellular matrix: including actin cytoskeleton, extracellular matrix, axon guidance, cell adhesion proteins, focal adhesion, and tight junction KEGG gene sets; (ii) metabolism: valine isoleucine degradation, ether lipid metabolism and propanoate metabolism; (iii) transcriptional regulation: transcriptional misregulation in cancer; (iv) RAS/ mitogen-activated protein kinase: mitogen-activated protein kinase signaling; (v) PI3K/mTOR: PI3K-AKT and mTOR; (vi) WNT; (vii) receptors with tyrosine kinase activity (RTKs): with many RTKs and associated downstream signaling included in multiple KEGG gene sets such as, for example, neurotrophin signaling, pathways in cancer, non-small cell lung cancer or, ErbB signaling, to name but a few; (viii) cAMP/CRE-binding protein: included in alcoholism and amphetamine addiction; (ix) calcium: vascular smooth muscle contraction or glutaminergic signaling, and (x) other. According to our data, these might act as disease mechanisms in MCC ( Figure 1c , and see Supplementary Table S8) . We next studied the expression of specific MCC biomarkers, such as MCPyV, p63, RB, and TP53, in conjunction with specific transcription factors such as activated surrogate IHC markers corresponding to the signaling pathways described earlier. For this purpose, we considered 48 clinically characterized MCC patients (henceforth referred to as the validation cohort), of whom 15 had been included in the genomic study (see the clinical characteristics in Supplementary Table S1 ). Along with the aforementioned biomarkers, we analyzed the nuclear expression of b-catenin and LEF-1 (WNT pathway), P-CREB (cAMP/ CRE-binding protein), NFAT (calcium), C-MYC, and P-STAT (RTKs) in our validation cohort of samples (Table 2) . Our results showed that MCPyV þ lesions had a homogeneous expression landscape, with a uniform staining pattern for specific markers, such as b-catenin (positive in the membrane) and RB (positive) and C-MYC and LEF-1 (negative), and heterogeneous staining for TP53, p63, P-CREB, and NFAT. P-STAT was detected in only four of the 26 MCPyV þ patients. On the other hand, MCPyV e lesions showed heterogeneous biomarker expression. In total, 50% of the patients had a loss of RB expression, whereas for C-MYC and LEF-1, expression was detected almost exclusively in MCPyV e patients but was limited to about half of these patients (Table 2) . A representation of IHC markers for a representative MCPyV þ and MCPyV e patient is shown in Figure 2 . Despite the different genomic characteristics observed between MCPyV þ and MCPyV e lesions, it is possible that the two MCC etiologies share common disease mechanisms (TP53, RB, NFAT, P-STAT, and P-CREB), with MCPyV e lesions developing additional molecular features.
Biological relevance derived from the characterization of MCC tumors
To explore the clinical implications of the molecular mechanisms (biomarkers) identified in this work, we studied their association with the clinical outcome of the patients in our validation cohort. The clinical data for each patient are summarized in Supplementary Table S1 . We analyzed the death events caused by MCC in different sets of patient tumors characterized with respect to the positive or negative expression of each biomarker depicted as follows: (i) biomarkers already studied by other groups in different cohorts of patients, that is, MCPyV, TP53, RB, and p63 and (ii) biomarkers expressed in both MCPyV þ and MCPyV e tumors: NFAT, P-CREB, and P-STAT. We could not include biomarkers in this study that were mainly expressed in MCPyV e tumors (C-MYC and LEF1) alone because of the limited cohort size. As expected, and in accordance with previous observations by other laboratories (Carson et al., 1998; Nardi et al., 2012; Sihto et al., 2011; Waltari et al., 2011) , MCC patients with tumors that were negative for the expression of MCPyV and RB tended to have a poorer clinical outcome, whereas, at least in our hands, TP53, p63, and NFAT did not show this tendency (see Supplementary  Figure S1 online).
Those cancers that tested positive for the expression of P-CREB or P-STAT showed significantly shorter survival than their negative counterparts (P ¼ 0.011 and P ¼ 0.024, respectively), with a crude hazard ratio of 3.89 for P-CREB and 3.37 for P-STAT (Figure 3) . We decided to perform Note. Assessment of the expression of specific markers by immunohistochemistry. All these markers are related to pathways detected by an unbiased approach as being especially altered in tumor samples. Boldface type indicate potentially pathogenic markers. Abbreviations: P-CREB, phosphorylated CRE-binding protein; P-STAT, phosphorylated signal transducer and activator of transcription; RB, retinoblastoma; MCPyV, Merkel cell polyomavirus.
DISCUSSION
MCC is a type of cancer with increasing incidence and a high mortality rate. Despite recent advances in our understanding of the main biological mechanisms involved in its clinical evolution, we still know little about the molecular biology of this disease, as is reflected by the current lack of any specific therapy (Becker, 2010; Hughes et al., 2014) . In this study, we used a combination of genomic techniques and clinical data to mechanistically and biologically characterize MCC tumors. These methods included deepsequencing approaches (whole-exome sequencing) in samples from 15 patients (the discovery cohort) and a selection of immunohistochemical markers in 48 samples from MCC patients (the validation cohort).
First, we found different genetic patterns of disease mechanisms in our cohort of patients with MCPyV Crude hazard ratio and hazard ratio adjusted for P-STAT3, P-CREB, MCPyV status, sex, age, and stage, with 95% confidence intervals. CI, confidence interval; HRa, adjusted hazard ratio; HRc, crude hazard ratio; MCC, Merkel cell carcinoma; P-CREB, phosphorylated CRE-binding protein; P-STAT, phosphorylated signal transducer and activator of transcription. accumulated most of the detected somatic mutations, giving an average mutational index of 20 amino acid-changing mutations/megabase and a UV signature comparable to that of malignant melanoma (C>T at dipyrimidine sites above 60% of the total SSMs) (The Cancer Genome Atlas Network, 2015; Goh et al., 2015; Harms et al., 2015; Wong et al., 2015) . By contrast, MCPyV þ tumors had lower mutational indexes (average mutational index ¼ 0.75 amino acidchanging mutations/megabase) that are similar to those observed for small B-cell lymphomas . To provide our mutational data with a functional interpretation we used an unbiased approach (OncodriveFM), which enabled us to identify specific genes and pathways that were significantly altered in our MCC samples, presumably with the potential to participate as disease mechanisms in MCC. We explored this possibility by focusing on the expression of a group of transcription factors as endpoint surrogates for the activity of the genes and signaling pathways identified in this study. These included b-catenin and LEF-1 (WNT pathway [Duchartre et al., 2016] ), NFAT (calcium, reviewed in Mognol et al., 2016) , P-CREB (cAMP/CRE-binding protein signaling [Rodriguez and Setaluri, 2014] ), P-STAT (RTKs signaling, reviewed in Yu et al., 2014) and C-MYC (RAS/ mitogen-activated protein kinase, PI3K, and RTKs signaling pathways [Kress et al., 2015] ), along with MCPyV, TP53, p63, and RB (previously identified MCC biomarkers [Zager et al., 2011] ) (Figures 1 and 4) .
Our data enabled a number of MCC mutations (with a previous identification number in the Catalogue of Somatic Mutations in Cancer identification, as shown in Supplementary Table S3 ) to be associated with specific biomarker expression in MCC samples from the validation cohort (Table 2 and Figure 1 ). For example, in patient 5 we detected two potentially inactivating TP53 mutations provoking amino-acid changes, R280K (COSM129830) and H47Y (COSM129851), and a truncating RB1 mutation (W195*, COSM214151) with positive (TP53) and negative (RB) protein expression. These can be due to a direct effect on a specific gene, but we cannot rule out potential indirect effects of specific gene mutations on the activity of its associated signaling pathway (see Figure 4) . In this regard and to serve as an example, HIVEP2 (also known as Myc intron binding protein 1, MIBP1) is a significantly mutated gene in our analysis, detected in patients 1, 3, 7 (missense mutations), and 6 (a truncating mutation). In our work, IHC data showed positive results for C-MYC in patients 1, 3, and 6, suggesting a potential correlation between MIBP1 mutations (presumably inactivating) and C-MYC expression. Furthermore, it has been shown that MIBP1 can inhibit transcription of C-MYC (Iwashita et al., 2012) , and the expression of both genes has been shown to be inversely correlated in human cells (ZajacKaye et al., 2000) . Also, ERBB4 mutations in patients 1 (two missense mutations) and 6 (R711C, COSM160827) could contribute to activating c-MYC and STAT (see also Figure 4 ). On the other hand, we detected a large number of mutations in adenylate cyclases and G-protein coupled receptors that could participate in cAMP/CRE-binding protein activation, for example ADCY10-P241H (COSM899133) and GRM3-E538K (COSM229505), which were found in patient 1 (PCREBepositive). In our study, perhaps with the exception of TP53, we did not detect hotspot mutations with functional validation to predict activation or repression of a specific signaling pathway. It is possible that pursuing the study of inactivating mutations in MIBP1 or presumably activating mutations such as ERBB4-R711C could improve our ability to understand important MCC oncogenic mechanisms. Nevertheless, it is conceivable that by analyzing the expression of a specific subset of biomarkers in MCC samples, we could detect deregulated mechanisms of disease, as might be expected given the mutational data. From a mechanistic perspective, and despite substantial differences in the number of mutations, the MCPyV þ and MCPyV e tumors examined here unexpectedly shared several deregulated signaling mechanisms, as indicated by the detection of specific biomarkers such as P-STAT, P-CREB, and NFAT in samples from our validation cohort of MCC patients. On the other hand, we also found that C-MYC and LEF1 were expressed almost exclusively in MCPyV e patients. At first glance, this could be due to nothing more than the accumulation of somatic mutations in this type of MCC tumor. However, MCPyV þ patients showed activated P-STATe, P-CREBe, and NFATeassociated signaling in the absence of specific mutations, resulting in the mechanistic mimicry of MCPyV e tumors. In our opinion, these findings suggest that MCPyV e tumors with high mutational loads can acquire specific biological properties through the activation of alternative oncogenic pathways including, but not restricted to, those detected in this work: C-MYC and LEF1. Our results strongly suggest a need for further studies that would determine their contribution to the biology and targeted therapy of this disease.
From a biological perspective, the ability of a range of markers to predict a worse clinical evolution of MCC patients has been examined. Of these, MCPyV e tumors (Nardi et al., 2012) , p63 expression (Asioli et al., 2007) , and the percentage of MCC cells expressing Ki67 (Llombart et al., 2005) have been proposed as factors associated with bad prognosis. We found a tendency toward worse survival in patients characterized with specific biomarkers used individually: MCPyV e and RB e . Under these circumstances, it is possible that more significant results could be obtained from additional methods that attempt to better determine the status of specific biomarkers such as TP53, or from increasing the cohort size. Two mechanisms shared by MCPyV þ and MCPyV e MCC tumors were highly significant predictors of survival: P-CREB and P-STAT. A multivariable analysis detected P-CREB as being a strong predictor of mortality independent of sex, age, stage, MCPyV status, and P-STAT. Thus, our findings argue for a potential role for these disease mechanisms in the biological evolution of both types of MCC lesions. Further efforts should be made to explore the biological role of these markers in larger series of samples from clinically characterized MCC patients. Our results also suggest that a better characterization of the molecular mechanisms that can control CREB activation in MCC cancers with different MCPyV status could be useful for developing tools for diagnosis, prognosis, and treatment of this disease.
In summary, we characterized a cohort of MCC patients using an original combination of genomic and IHC approaches applied to this field. Confirming previous data, we found two distinct etiologies with clearly divergent mutational signatures. Despite these differences, the data arising from our work show that MCPyV þ and MCPyV e MCC tumors can develop similar mechanisms of disease with clinical implications for patient survival and potential to serve as targets for therapy. Moreover, a subset of MCC patients with CRE-binding protein and/or signal transducer and activator of transcription activation developed a more aggressive disease that was associated with worse survival. In fact, within our patient cohort, we found P-CREB to be a strong independent survival factor for this disease. Thus, in the current MCC clinical setting, upon mechanistic characterization of MCC tumors at diagnosis, we may be able to predict poorer outcomes and explore approaches for specific therapy.
MATERIALS AND METHODS
Ethics statement
All human samples used in this study were collected following the Declaration of Helsinki protocols after obtaining written informed consent from each patient and the doctors involved, as required by the Comité Ético de Investigació n Clínica, Cantabria (CEIC). We kept the original records under specific restricted conditions to fulfill the current legal requirements. All processes were approved and conducted in adherence with the specific recommendations of the CEIC.
Patient samples
Samples from 48 clinically characterized MCC patients were used (validation cohort; see Supplementary Table S1 ). From these, 15 patients (discovery cohort; Table 1 , and see Supplementary Table S1 ) with a total of 30 paired (nontumoral and tumoral) formalin-fixed, paraffinembedded and freshly frozen samples were selected for whole-exome sequencing analysis. Patients were included consecutively.
Additional methods
See Supplementary Materials online. Supplementary data is also included, since it is a single file with additional methods and supplementary information.
